IJCS | Volume 31, Nº5, September / October 2018

546 Table 1 - Demographic, laboratory, echocardiographic parameters and Charlson comorbidity indices of the groups. (Data with normal distribution were expressed as mean ± SD, and data with abnormal distribution were expressed as min-max; median) Ocluded graft (n = 54) Patent graft (n = 48) p Age (years) 43 - 89; 66.5 47 - 83; 66 0.72 Gender (M, n) 44 31 0.06 Systolic blood pressure (mm Hg) 90 - 190; 127 90 - 180; 130 0.87 Diastolic blood pressure (mm Hg) 78.5 ± 12.2 78.0 ± 11.0 0.85 Heart rate (beat/min) 58 - 114; 82 53 - 106; 78 0.18 SAH (n) 39 32 0.65 DM (n) 25 19 0.55 Family history of CAD (n) 13 12 0.86 Hyperlipidemia (n) 31 30 0.51 Smoking (n) 11 9 0.67 Duration (years) 1 - 23; 8 2 - 22; 7.5 0.97 Total cholesterol (mg/dL) 105 - 289; 185 129 - 351; 210 0.11 Triglyceride (mg/dL) 56 - 641; 140 62 - 507; 184 0.22 HDL (mg/dL) 45.9 ± 11.7 44.6 ± 12.8 0.65 LDL (mg/dL) 114.1 ± 40.1 123.1 ± 42.9 0.32 CCI 7.1 ± 2.0 4.7 ± 1.6 < 0.001 Modified CCI 6.1 ± 2.0 3.7 ± 1.6 < 0.001 Occluded IMA (n) 4 - Occluded saphenous graft (n) 50 - Occluded radial graft 0 - EF (%) 45.0 ± 8.2 46.9 ± 9.9 0.36 Beta blocker (n) 29 18 0.41 ACEI (n) 46 39 0.42 Statin (n) 25 20 0.13 Nitrate (n) 6 2 0.33 Diuretic (n) 12 9 0.95 OAD (n) 20 18 0.23 Insulin (n) 7 5 0.43 Abbrevations: M: male, SAH: sstemic arterial hypertension, DM: diabetes mellitus, CAD: coronary artery disease, HDL: high density lipoprotein, LDL: low density lipoprotein, CCI: Charlson comorbidty index, IMA: internal mammary artery, EF: ejection fraction; ACEI: angiotensin-converting enzyme inhibitor; OAD: oral antidiabetic drugs. Karabag et al. Comorbidity and graft patency Int J Cardiovasc Sci. 2018;31(5)544-547 Brief Communication